Regulatory
Sep 13, 2026 · 1 min read · 42,540 views
FDA offers little comment on Grail cancer test ahead of adcomm
M
Maya Chen
Editorial · Sep 13, 2026
Before its advisory committee meetings, the FDA typically releases briefing documents to provide positive or negative perspective on whether a treatment works or is safe. But in the case of Wednesday's meeting of the FDA's
← Previous
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
Next →
Max Gelman - Endpoints News
